What Your Cholesterol Panel Tells You — and What It Doesn't

We're hearing more about the limitations of standard lipid panels, the importance of ApoB, and why lipoprotein(a), or Lp(a), should be measured. Much of that discussion is justified. We have better tools for understanding cardiovascular risk than we did in the past.

But there's an important point that sometimes gets lost in all of this:

Even an expanded lipid panel is still only one part of understanding your cardiovascular health.

And cardiovascular health itself is only one part of your overall health.

What does a lipid panel actually tell us?

A standard lipid panel measures total cholesterol, HDL cholesterol, and triglycerides, and typically reports an LDL cholesterol value.

Of these measurements, LDL cholesterol is particularly important. LDL particles contribute to the development of atherosclerosis, the accumulation of plaque within our arteries. Over time, this can lead to coronary artery disease, heart attacks, ischemic strokes, and vascular disease affecting other organs.

But LDL cholesterol doesn't tell us everything.

That's where additional measurements like ApoB and Lp(a) become useful.

ApoB helps us understand the number of potentially atherosclerosis-causing particles circulating in the blood. LDL cholesterol tells us how much cholesterol is carried within LDL particles, while ApoB gives us a better estimate of the number of atherogenic particles themselves. These measurements are related, but they don't always tell exactly the same story.

Lp(a) adds another dimension. It's a largely inherited lipoprotein that can increase cardiovascular risk independently of traditional cholesterol measurements. Unlike LDL cholesterol, Lp(a) levels generally change very little in response to diet, exercise, or other lifestyle interventions.

That doesn't mean an elevated Lp(a) leaves us helpless. It means we should be more intentional about managing the other cardiovascular risks we can modify.

Generally speaking, greater exposure to atherogenic lipoproteins over time means greater risk of developing atherosclerotic cardiovascular disease.

And reducing that exposure can reduce future risk.

What can we actually do about these numbers?

A great deal, particularly when it comes to LDL cholesterol and ApoB.

We can start with lifestyle.

Improving dietary quality, reducing saturated fat intake where appropriate, replacing it with healthier unsaturated fats, increasing soluble fiber, and establishing regular exercise habits can all contribute to better cardiovascular health.

Exercise is especially interesting because its cardiovascular benefits extend beyond what we see on a lipid panel. Aerobic fitness, blood pressure, insulin sensitivity, and vascular function may all improve even when LDL cholesterol changes only modestly.

And sometimes lifestyle changes aren't enough.

There may be a significant genetic component to someone's cholesterol levels. Even an excellent diet and consistent exercise routine may not lower LDL cholesterol or ApoB sufficiently for that person's level of risk.

That's where medications can play an important role.

We have effective oral medications and injectable therapies that can substantially lower atherogenic cholesterol levels and reduce cardiovascular events.

The goal isn't to avoid medications at all costs, nor is it to put everyone on medication. It's to understand the individual's risk and use the appropriate tools to reduce it.

But cholesterol is not the whole cardiovascular picture

Imagine two people with identical LDL cholesterol and ApoB measurements.

One exercises regularly, has excellent cardiorespiratory fitness, maintains healthy blood pressure and glucose levels, doesn't smoke, and has good sleep habits.

The other is sedentary, has poorly controlled blood pressure, insulin resistance, smokes, and has poor sleep.

Their lipid measurements may be identical.

Their overall cardiovascular risk is not.

This is why we need to look beyond the lipid panel.

Blood pressure, metabolic health, diabetes, smoking, kidney function, family history, physical activity, and other factors contribute to cardiovascular risk.

Additional testing may also provide useful information.

VO2 max testing can help us understand cardiorespiratory fitness, an important predictor of long-term health outcomes.

DEXA scanning can provide insight into body composition, including visceral adiposity, which is relevant to cardiometabolic health.

And in appropriately selected patients, coronary artery calcium scoring can provide more direct information about existing calcified coronary atherosclerosis and help guide treatment decisions.

These tests aren't interchangeable, and not everyone needs all of them. Each provides a different piece of information.

The bigger picture

A lipid panel is important. An expanded lipid assessment can be even more informative.

But neither should be interpreted in isolation.

We need to understand what the measurements mean, how they interact with other risk factors, what they tell us about an individual's future health, and, most importantly, what we can do with that information.

The objective isn't simply to collect more tests or achieve better-looking laboratory numbers.

It's to understand risk, identify opportunities to intervene, and make meaningful changes that improve health over time.

That's where comprehensive medicine becomes valuable.

Better measurements help us understand risk. Better interpretation helps us change it.